EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A 5‐year natural history cohort of patients with facioscapulohumeral muscular dystrophy determining disease progression and feasibility of clinical outcome assessments for clinical trials

Joost Kools iD, Sanne Vincenten iD, Baziel G M van Engelen, Nicoline B M Voet iD, Ingemar Merkies, Corinne G C Horlings, Nicol C Voermans iD, K Mul

Muscle & Nerve · 2025

DOI: 10.1002/mus.28293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Muscle & Nerve, 2025. Verfasst von Joost Kools und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Muscular Dystrophy, Facioscapulohumeral, Disease Progression, Feasibility Studies, Muscle Strength. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Charitable Foundation Prinses Beatrix Spierfonds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims The number of clinical trials in facioscapulohumeral muscular dystrophy (FSHD) is expected to increase in the near future. There is a need for clinical outcome assessments (COAs) that can capture disease progression over the relatively short time span of a clinical trial. In this study, we report the natural progression of FSHD and determine the feasibility of COAs for clinical trials.

Methods

Genetically confirmed FSHD patients underwent various COAs at baseline and after 5 years. COAs consisted of the Motor Function Measure (MFM), manual muscle testing using the Medical Research Council score, six‐minute walk test, quantitative muscle strength assessment of the quadriceps muscle, clinical severity score, and FSHD evaluation score (FES). Statistical significance and the minimal clinically important difference (MCID) were calculated and power calculations were performed.

Results

One hundred fifty‐four symptomatic FSHD patients were included, with a mean (SD) age of 51.4 (14.6) years old. All COAs showed a minimal, yet statistically significant progression after 5 years. MCID was reached for the MFM Domain 1, MFM total score, and FES. These three COAs showed the lowest sample size requirements for clinical trials (185, 156, and 201 participants per group, respectively, for a trial duration of 2 years).

Discussion

The captured FSHD disease progression rate in 5 years was generally minimal. The COAs in this study are not feasible for clinical trials with a duration of 2 years. Extended trial durations or novel outcome assessments might be necessary to improve trial feasibility in FSHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, FacioscapulohumeralDisease ProgressionFeasibility StudiesMuscle StrengthHumansMaleFemaleMiddle AgedAdultAgedOutcome Assessment, Health CareCohort StudiesClinical Trials as TopicSeverity of Illness IndexWalk Test

Stichwörter der Autor:innen

FSHDclinical outcome assessmentsdisease progressionminimal clinically important differencepower calculation

Autor:innen und Institutionen

  • Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Klimmendaal, Rehabilitation Center, Arnhem, The Netherlands.
  • Department of Rehabilitation, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Neurology, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Department of Neurology, Curaçao Medical Center, Willemstad, Curaçao.
  • Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

ORCID-Profile: Joost Kools, Sanne Vincenten, Nicoline B M Voet, Nicol C Voermans

Förderung

  • Charitable Foundation Prinses Beatrix Spierfonds

Zitieren

APA

Kools, J., Vincenten, S., van Engelen, B. G. M., Voet, N. B. M., Merkies, I., Horlings, C. G. C., Voermans, N. C., & Mul, K. (2025). A 5‐year natural history cohort of patients with facioscapulohumeral muscular dystrophy determining disease progression and feasibility of clinical outcome assessments for clinical trials. Muscle & Nerve. https://doi.org/10.1002/mus.28293

Vancouver

Kools J, Vincenten S, van Engelen BGM, Voet NBM, Merkies I, Horlings CGC, et al. A 5‐year natural history cohort of patients with facioscapulohumeral muscular dystrophy determining disease progression and feasibility of clinical outcome assessments for clinical trials. Muscle & Nerve. 2025. doi:10.1002/mus.28293

BibTeX
@article{Kools2025,
  author = {Kools, Joost and Vincenten, Sanne and van Engelen, Baziel G M and Voet, Nicoline B M and Merkies, Ingemar and Horlings, Corinne G C and Voermans, Nicol C and Mul, K},
  title = {A 5‐year natural history cohort of patients with facioscapulohumeral muscular dystrophy determining disease progression and feasibility of clinical outcome assessments for clinical trials},
  journal = {Muscle & Nerve},
  year = {2025},
  doi = {10.1002/mus.28293}
}
Kostenlos starten →